Abstract
Patient access to safe and cost-effective treatment is an important goal for the healthcare system. The development of biosimilar compounds and generic medicines is interesting to the industry and society to reduce healthcare costs, fulfill the needs of healthcare stakeholders and potentially increase accessibility to patients. Patient and physician acceptance, with many patients preferring biologics and branded products and physicians prescribing the same, limits the use of generic medicine and biosimilars. The growth of these products in part depends on various stakeholders’ decisions to provide, pay for or use these products in a safe and thoughtful manner. Ongoing stakeholder collaboration, educational activities and review of current government and payer policies are required to optimize the uptake of generic medicines and biosimilars.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Birkett, D. J. 2003. Generics – equal or not? Australian Prescriber 26, 85–87.
Choudhry, N. K., Denberg, T. D. & Qaseem, A. 2016. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med, 164, 41–9.
Colgan, S., Faasse, K., Martin, L. R., Stephens, M. H., Grey, A. & Petrie, K. J. 2015. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open, 5, e008915.
Crawford, P., Feely, M., Guberman, A. & Kramer, G. 2006. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure, 15, 165–76.
Dylst, P. & Simoens, S. 2010. Generic Medicine Pricing Policies in Europe: Current Status and Impact. Pharmaceuticals (Basel, Switzerland), 3, 471–481.
Dylst, P., Vulto, A. & Simoens, S. 2013. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res, 13, 59–72.
Gothe, H., Schall, I., Saverno, K., Mitrovic, M., Luzak, A., Brixner, D. & Siebert, U. 2015. The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Appl Health Econ Health Policy, 13 Suppl 1, S21–33.
Hassali, M. A., Alrasheedy, A. A., Mclachlan, A., Nguyen, T. A., Al-Tamimi, S. K., Ibrahim, M. I. & Aljadhey, H. 2014a. The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J, 22, 491–503.
Hassali, M. A., Wong, Z. Y., Alrasheedy, A. A., Saleem, F., Mohamad Yahaya, A. H. & Aljadhey, H. 2014b. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy, 117, 297–310.
Kaplan, W. A., Ritz, L. S., Vitello, M. & Wirtz, V. J. 2012. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy, 106, 211–24.
Kesselheim, A. S., Misono, A. S., Lee, J. L., Stedman, M. R., Brookhart, M. A., Choudhry, N. K. & Shrank, W. H. 2008. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. Jama, 300, 2514–26.
Kesselheim, A. S., Stedman, M. R., Bubrick, E. J., Gagne, J. J., Misono, A. S., Lee, J. L., Brookhart, M. A., Avorn, J. & Shrank, W. H. 2010. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs, 70, 605–21.
King, D. R. & Kanavos, P. 2002. Encouraging the use of generic medicines: implications for transition economies. Croat Med J, 43, 462–9.
Liberman, J. N. & Roebuck, M. C. 2010. Prescription drug costs and the generic dispensing ratio. J Manag Care Pharm, 16, 502–6.
Posner, J. & Griffin, J. P. 2011. Generic substitution. British journal of clinical pharmacology, 72, 731–732.
Razmaria, A. A. 2016. Generic Drugs Generic Drugs JAMA Patient Page. JAMA, 315, 2746–2746.
Royal Dutch Pharmacists Association 2012. Guideline for generic substitution. The Hague, The Netherlands.
Shafie, A. A. & Hassali, M. A. 2008. Price Comparison between Innovator and Generic Medicines Sold by Community Pharmacies in the State of Penang, Malaysia. Journal of Generic Medicines, 6, 35–42.
Straka, R. J., Keohane, D. J. & Liu, L. Z. 2017. Potential Clinical and Economic Impact of Switching Branded Medications to Generics. Am J Ther, 24, e278–e289.
Theodorou, M., Tsiantou, V., Pavlakis, A., Maniadakis, N., Fragoulakis, V., Pavi, E. & Kyriopoulos, J. 2009. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. BMC Health Serv Res, 9, 150.
Toverud, E. L., Hartmann, K. & Hakonsen, H. 2015. A Systematic Review of Physicians’ and Pharmacists’ Perspectives on Generic Drug Use: What are the Global Challenges? Appl Health Econ Health Policy, 13 Suppl 1, S35–45.
Us Food & Drug Administration. What standards must generic medicines meet to receive FDA approval? [Online]. Available: https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers [Accessed].
Young, J. D. 1994. Prescribing generic drugs. The British journal of general practice: the journal of the Royal College of General Practitioners, 44, 139–140.
Alten, R, Cronstein, BN. Clinical trial development for biosimilars. Seminars in Arthritis and Rheumatism 2015; 44:S2–S8. doi:https://doi.org/10.1016/j.semarthrit.2015.04.002.
Berghout, A. Clinical programs in the development of similar biotherapeutic products: Rationale and general principles. Biologicals. 2011 Sep;39(5):293–6. doi:https://doi.org/10.1016/j.biologicals.2011.06.024
Blackstone, EA, Joseph, PF. The economics of biosimilars. Am Health Drug Benefits. 2013 Sep;6(8):469–78. https://www.ncbi.nlm.nih.gov/pubmed/24991376
Calvo, B, Zuniga, L. InTech. Risk management plan and pharmacovigilance system- biopharmaceuticals: biosimilars, http://www.intechopen.com/books/risk-management-trends/risk-managementplan-and-pharmacovigilance-system-biopharmaceuticals-biosimilars; 2011
Casadevall, N, Edwards, IR, Felix, T, Graze, PR, Litten, JB, Strober, BE, Warnock, DG. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther. 2013 Jul;13(7):1039–47. doi: https://doi.org/10.1517/14712598.2013.783560.
Choy, E, Jacobs, IA. Biosimilar safety considerations in clinical practice. Safety issues – Semin Oncol. 2014 Feb;41 Suppl 1:S3–14. doi: https://doi.org/10.1053/j.seminoncol.2013.12.001.
Cohen, HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018 Mar;78(4):463–478. doi: https://doi.org/10.1007/s40265-018-0881-y.
Crespi-Lofton, J, Skelton, JB. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder. J Am Pharm Assoc (2003). 2017 Sep – Oct;57(5):e15–e27. doi: https://doi.org/10.1016/j.japh.2017.05.014.
do REIS, C, Ricardo, T, Fernando, M, Rui Santos, C. Biosimilar medicines – Review. International Journal of Risk and Safety in Medicine, 2016 vol. 28, no. 1, pp. 45–60, 2016. DOI: https://doi.org/10.3233/JRS-160672
European Medicines Agency (EMA). Biological medicine. https://www.ema.europa.eu/en/glossary/biological-medicine
European Medicines Agency (EMA). Improving understanding of biosimilars in the EU. 13/09/2018. https://www.ema.europa.eu/en/news/improving-understanding-biosimilars-eu
European Medicines Agency (EMA). Biosimilar medicines: Overview. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview (n.d.)
Feagan, B. Benefits, concerns, and future directions of biosimilars in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13(12):745–747. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763561/
Feagan, BG, Lam, G, Ma, C, Lichtenstein, GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019 Jan;49(1):31–40. doi: https://doi.org/10.1111/apt.14997
Kaida-Yip, F, Deshpande, K, Saran, T, Vyas, D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018;6(8):161–166. doi:https://doi.org/10.12998/wjcc.v6.i8.161. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107532/
Knuts, B. Biosimilars, no generic biologicals! J Pharm Belg. 2016 Dec;(4):24–29;
Kramer, I. Biosimilars. Ther Umsch. 2011 Nov;68(11):659–66. doi: https://doi.org/10.1024/0040-5930/a000227.
Liu, Y, Yang, M, Garg, V, Wu, EQ, Wang, J, Skup, M. Economic impact of non- medical switching from originator biologics to biosimilars: a systematic literature review. Advances in Therapy August 2019, Volume 36, Issue 8, pp 1851–1877
NHS England. What is a Biosimilar Medicine? Medicines and Diagnostics Policy Unit, Specialised Commissioning, NHS England and NHS Improvement. 30 May 2019. https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf.
Pineda, C, Caballero-Uribe, CV, de oliveira, MG, Lipszyc, PS, Lopez, JJ, Moreira, MMM, Azevedo, VF. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol (2015) 34:635–640. DOI https://doi.org/10.1007/s10067-015-2887-0
Pouillon, L, Socha, M, Demore, B, Thilly, N, Abitbol, V, Danese, S & Peyrin-Biroulet, L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Review of Clinical Immunology 2018;14:739–49. DOI: https://doi.org/10.1080/1744666X.2018.1512406
Purcell, RT, Lockey, RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 2008;18:335–42.
Reinisch, W, Smolen, J. Biosimilar safety factors in clinical practice. Seminars in Arthritis and Rheumatism 2015; 44: S9–S15.
Reno, J. Biosimilar drugs could save money and lives. So why don’t we use them? July 27, 2018. https://www.healthline.com/health-news/biosimilar-drugs-save-money-and-lives-why-dont-we-use-them#1
Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Reviews Drug Discovery 2002; 1:457–462.
Smeeding, J, Malone, DC, Ramchandani, M, Stolshek, B, Green, L, Schneider, P. Biosimilars: Considerations for Payers. P T. 2019;44(2):54–63.
United States Food and Drug Administration (US FDA). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
United States Food and Drug Administration (US FDA). What is biosimilar. https://www.fda.gov/media/108905/download
United States Food and Drug Administration (US FDA). Biological Product Definitions. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM581282.pdf
United States Food and Drug Administration (US FDA). Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf.
United States Food and Drug Administration (US FDA). Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
van Bodegraven, A. A., Boone, N.W. Editorial: nocebo effect and switching to biosimilars. Alimentary Pharmacology & Therapeutics 2018;47:850–51. https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14509.
Yoo, DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev. Clin Immunol. 2014;10:981–983. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107532/#B20
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Important Links and Websites
Important Links and Websites
Below are a few important links for further reading:
-
US Food & Drug Administration. Generic Drugs.https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs
-
US Food & Drug Administration. Generic Drugs: Questions & Answers. https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers
-
The Association for Accessible Medicines. Generic Medicines. https://accessiblemeds.org/generic-medicines
-
Generics and Biosimilars Initiative Journal: http://gabi-journal.net/
-
Guidelines for Substitution of Generics in the Netherlands http://www.gabionline.net/layout/set/print/Guidelines/Guidelines-for-substitution-of-generics-in-The-Netherlands
-
Davit et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583–97. Available at: https://doi.org/10.1345/aph.1M141
-
IQVIA Institute for Human Data Science: Reports. Available from: https://www.iqvia.com/institute/reports/reports-archive
-
The Center for Biosimilars. Available at: https://www.centerforbiosimilars.com/news/nhs-publishes-update-on-the-use-of-biosimilars
-
United States Food & Drug Administration. Available at: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
-
Dove Medical Press. Available at: https://www.dovepress.com/biosimilars-archive113
-
The Pharmaceutical Journal. Available at: https://www.pharmaceutical-journal.com/104319.subject?firstPass=false
Rights and permissions
Copyright information
© 2020 The Author(s)
About this chapter
Cite this chapter
Mohamed Ibrahim, M.I., Awaisu, A. (2020). Generic Medicines and Biosimilars: Impact on Global Pharmaceutical Policy. In: Babar, ZUD. (eds) Global Pharmaceutical Policy. Palgrave Macmillan, Singapore. https://doi.org/10.1007/978-981-15-2724-1_3
Download citation
DOI: https://doi.org/10.1007/978-981-15-2724-1_3
Publisher Name: Palgrave Macmillan, Singapore
Print ISBN: 978-981-15-2723-4
Online ISBN: 978-981-15-2724-1
eBook Packages: Social SciencesSocial Sciences (R0)